A Phase I, Open Label, Study of 3,4-Methylenedioxymethamphetamine (MDMA) Tolerability and Pharmacokinetics in Subjects With Moderate Hepatic Impairment Compared to Matched Control Subjects With Normal Hepatic Function

The goal of this clinical trial to learn how MDMA is processed in people with abnormal liver function.
The main questions it aims to answer are:
Do people with abnormal liver function experience greater absorption of MDMA? Does the dose of MDMA need to be adjusted in people with abnormal liver function?
Researchers will compare people with abnormal liver function to people with normal liver function.
Participants will receive a single dose of MDMA then undergo periodic vitals measurements. They will remain at the study site for two more days undergoing more vitals measurements and having subjective effects and adverse events measured.

开始日期2026-03-29

申办/合作机构

Lykos Therapeutics, Inc.

NCT04454684

/ Withdrawn临床2期

An Open-Label, Multi-Site Phase 2 Study of the Safety and Feasibility of MDMA-Assisted Psychotherapy for Eating Disorders

The goal of this clinical trial is to learn if MDMA-assisted therapy and caregiver involvement are safe and effective in treating female participants with eating disorders.
The main question it aims to answer is: Does MDMA-assisted therapy reduce eating disorder symptoms?
Participants will undergo two non-drug preparatory therapy sessions and their caregiver will undergo one non-drug preparatory therapy session. Participants will undergo three sessions of MDMA-assisted therapy followed by non-drug integrative therapy sessions alone as well as together with their caregiver.

开始日期2026-02-01

申办/合作机构

Lykos Therapeutics, Inc.

NCT05783817

/ Not yet recruiting临床2期IIT

MDMA-Assisted Cognitive Behavioral Therapy (CBT) Compared With Methamphetamine-Assisted CBT in Obsessive-Compulsive Disorder (OCD): A Phase II Study

The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).

开始日期2025-07-01

申办/合作机构

Stanford University

100 项与亚甲二氧甲基苯丙胺相关的临床结果

登录后查看更多信息

100 项与亚甲二氧甲基苯丙胺相关的转化医学

登录后查看更多信息

100 项与亚甲二氧甲基苯丙胺相关的专利（医药）

登录后查看更多信息

9,607

项与亚甲二氧甲基苯丙胺相关的文献（医药）

2025-12-31·European Journal of Psychotraumatology

Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder

Article

作者: Zeifman, Richard J. ; Mitchell, Jennifer M. ; Agin-Liebes, Gabrielle

Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcohol use disorder, and substance use disorders. A well-powered phase 3 randomized, placebo-controlled trial has shown that MDMA-assisted therapy (MDMA-AT) may be an effective treatment for severe PTSD. However, the psychological mechanisms driving the therapeutic effects of MDMA-AT remain unclear. One potential mechanism is self-compassion, which is commonly conceptualized as a balance between compassionate self-responding (CS) - encompassing self-kindness, common humanity, and mindfulness - and uncompassionate self-responding (UCS) - encompassing self-judgment, isolation, and over-identification.Objective: This secondary analysis aimed to explore whether MDMA-AT enhances aspects of self-compassion and if changes in self-compassion mediate the therapy's effectiveness in reducing PTSD severity, depressive, and alcohol and substance use symptoms.Method: Eighty-two adults diagnosed with severe PTSD participated in a double-blind trial comparing three sessions of either MDMA-AT or placebo combined with therapy. Measures of PTSD severity, depressive symptoms, alcohol and substance use, and self-compassion were collected at baseline and 18 weeks later.Results: MDMA-AT led to statistically significant improvements in both UCS and CS. Significant improvements were also observed across all six subscales of the Self-Compassion Scale, including self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification, most with large effect sizes. Changes in UCS and CS significantly and fully mediated the effects of MDMA-AT compared to placebo plus therapy in reducing PTSD severity and depressive symptoms. Findings were not significant for alcohol and substance use outcomes.Conclusions: These findings suggest that self-compassion may play a critical role in the therapeutic effects of MDMA-AT. Further research is needed to investigate the role of self-compassion in MDMA-AT to refine and develop more targeted, effective interventions for individuals with PTSD and co-occurring depression.

2025-10-01·TALANTA

Screening and validation of sponge materials assembled to a sampling device for enrichment and determination of amphetamine drugs in exhaled breath by HPLC-TQ-MS/MS

Article

作者: Yang, Xiangliang ; Xu, Fei ; Fan, Huajun ; Huang, Qingda ; Xu, Congfei ; Zhou, Jiedan ; Yang, Hai

Exhaled breath aerosol (EBA) analysis of the amphetamine drugs (AMPs) and ephedrine (EPH) has a great potential to monitor illicit drug abuse due to its simple, non-invasive, convenient, and easily accepted sampling. Nevertheless, the extremely low concentration of AMPs and EPH in EBA poses great challenges to instrumental analysis. In this study, a self-designed sampling device equipped with sponge-based material was developed and coupled to high-performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry (HPLC-TQ-MS/MS) for monitoring of the AMPs and EPH in EBA. Accordingly, the cellulose sponge with high adsorption performance and low expiratory resistance was screened out from multiple commercial sponges, optimized its configuration performance, and assembled to the sampling device, reaching the adsorption rates of 81.6 ± 2.2-98.9 ± 2.5 % for EPH and typical AMPs, including amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, and 3,4-methylenedioxymethamphetamine. The combination of HPLC-TQ-MS/MS and the device containing cellulose sponge showed excellent analytical performance, with linearity in the range of 30.0-20000.0 pg/filter (R ≥ 0.9901), low detection limit of 1.6-8.4 pg/filter, and the recoveries of 86.5-94.5 %. The device also exhibited good reusability and applicability for the simulated EBAs at different levels. Furthermore, the proposed method was successfully applied for determination of EPH in volunteers' EBAs, whose contents suggested a good correlation with that in saliva. Kinetic analysis provided insights into the adsorption mechanism, further validating reliability of the method. Overall, the simple, cheap, available, and reusable cellulose sponge assembled to sampling device was advantageous for enriching and monitoring of trace illicit drugs in human EBA.

2025-10-01·ADDICTIVE BEHAVIORS

Illicit drug use and associated health risk behaviors among sexual minority youth

Article

作者: Sciolla, Andres F ; Kelly, Deirdra ; Duong, Jeffrey

OBJECTIVE:

This study examined the links between lifetime illicit drug use (e.g., cocaine, hallucinogens, ecstasy, heroin) and proximal health risk behaviors among adolescents and investigated sexual identity as a moderator.

METHODS:

We analyzed data from the Center for Disease Control's 2021 Youth Risk Behavior Survey (N = 17,232), a biennial, cross-sectional survey of a nationally representative sample of youth enrolled in grades 9 through 12 in the United States. Bivariate tabulations of weighted data were used to estimate the prevalence of health risk behaviors among lifetime illicit drug users and sexual minority youth who identified as lesbian, gay, bisexual, questioning, or another sexual identity (LGBQ+). Structural equation modeling was used to examine their associations. Wald testing was employed to test for effect modification.

RESULTS:

Illicit drug use was associated with a broad range of health risk behaviors among adolescents (e.g., cigarette and marijuana use, drinking and driving, use of alcohol and drugs before sex, and having multiple sex partners). There was a significant interaction between lifetime illicit drug use and sexual identity such that LGBQ+ youth who have ever engaged in illicit drug use had the greatest odds of health risk behaviors.

CONCLUSIONS:

Adolescents with a history of ever using illicit drugs are likely to engage in a wide array of health risk behaviors. Screening and offering counseling on these health risk behaviors may play a crucial role in ensuring that the sequela of drug use among adolescents is minimized, especially for LGBQ+ youth.

466

项与亚甲二氧甲基苯丙胺相关的新闻（医药）

2025-07-01

·FierceBiotech

Beckley Psytech\'s psychedelic reduces depression symptoms in phase 2, triggering Atai merger

The psychedelics sector received a high-profile setback last year when the FDA rejected Lykos Therapeutics’ application for approval of its MDMA therapy for post-traumatic stress disorder. \n Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of a planned merger with mental health-focused company Atai Life Sciences.The phase 2b trial of 193 patients with treatment-resistant depression evaluated 8-mg and 12-mg doses of the drug, dubbed BPL-003, against a 0.3 mg comparator arm for eight weeks. BPL-003 is an intranasal formulation of mebufotenin or 5-MeO-DMT, a psychedelic substance belonging to the tryptamine family.A single 12-mg dose of BPL-003 was shown to result in the “statistically significant” 11.1-point decrease in depression symptoms at Day 29 as measured on the the Montgomery-Åsberg Depression Rating Scale (MADRS), compared to a 5.8-point decrease for the comparator arm, hitting the primary endpoint of the trial.Meanwhile, the 8-mg dose achieved a similar MADRS reduction of 12.1 points, which Atai said hit a key secondary efficacy endpoint for the study. As both doses appeared to demonstrate similar efficacy, Beckley and Atai suggested that the 8-mg dose “may be sufficient to achieve therapeutic benefit from a single dose.”“Notably, both the 8 mg and 12 mg doses of BPL-003 showed statistically significant improvements in MADRS scores as early as one day after dosing, with effects generally maintained out to week 8,” the companies explained in a July 1 release.When it came to safety, 99% of treatment-emergent adverse events were mild or moderate, said the companies, which noted that there were no drug-related serious adverse events nor suicide-related safety signals.The results hit the criteria required for Atai to proceed with its planned merger with Beckley Psytech, which was first set out last month. Assuming the plan is signed off by Atai’s shareholders, the resulting company, to be named Atai Beckley, should “create a global leader in short-time in-clinic psychedelic-based mental health therapies,” the companies said in this morning’s release. “The achievement of our primary and secondary endpoints in this study represents an important milestone in the development of BPL-003 and reinforces its potential to be a viable treatment option for patients and healthcare systems,” Beckley’s CEO Cosmo Feilding Mellen said in the release.“We are particularly encouraged that a single 8 mg or 12 mg dose of BPL-003 showed rapid and durable efficacy results, favourable tolerability and a short time in-clinic, giving us important flexibility in optimising the design of future trials,” the CEO added. “We now look forward to preparing for end-of-phase 2 meetings with regulators and moving forward with our strategic combination with Atai Life Sciences.”When it comes to nasal sprays for depression, Johnson & Johnson’s Spravato leads the way. The companies said the fact that the majority of patients in the phase 2 trial were deemed ready for discharge at the 90-minutes post-dose assessment “suggests BPL-003 could fit within the existing two-hour in-clinic interventional psychiatry treatment paradigm established by Spravato.”“These findings strengthen our confidence in the potential of BPL-003 to be a transformative psychedelic therapy, offering rapid and durable antidepressive effects with minimal in-clinic time for patients with treatment-resistant depression,” Atai CEO Srinivas Rao, M.D., said in the release. “We look forward to engaging with the regulators later this year to advance this innovative treatment into phase 3 clinical development.”The psychedelics sector received a high-profile setback last year when the FDA rejected Lykos Therapeutics’ application for approval of its MDMA therapy for post-traumatic stress disorder. But recent weeks have seen some good new emerge from the clinic, including a successful phase 3 depression readout for Compass Pathways’ psilocybin treatment.

$Beckley Psytech\'s psychedelic reduces depression symptoms in phase 2, triggering Atai merger$

临床2期临床结果临床3期

2025-06-13

·ir.cybin.com

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

- Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder (“MDD”) with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) - - Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company’s commercialization and manufacturing capabilities - - Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin’s clinical-stage pipeline - TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. “It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,” said Doug Drysdale, Chief Executive Officer of Cybin. “With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.” Recent Corporate Highlights Continued to expand its strategic clinical site partnership (“SPA”) program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance. Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003. Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline. Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows:U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular (“IM”) injection, including CYB004. U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular (“IM”) injection, including CYB004. Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics Recent statements and hiring decisions by senior U.S. Health and Human Services (“HHS”) and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways. The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include: In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a “top priority” and promised an “expeditious and rapid review” of clinical data.1 Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws.2 Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to “embrace” compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD.3 President Trump’s new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy.4 Cybin’s Chief Executive Officer Doug Drysdale recently appeared on Fox News and is increasingly sought by media outlets as a trusted commentator.5 On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows: Panel Title: The Home Stretch: Pivotal Trials and Preparing for Launch Date and Time: Thursday, June 19, 2025, at 9:30 a.m. MDT (11:30 a.m. EDT) About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram. Sources Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company’s partnership with Osmind; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company’s annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations. Neither Cboe Canada, nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. Investor & Media: Gabriel Fahel Chief Legal Officer Cybin Inc. 1-866-292-4601 irteam@cybin.com – or – media@cybin.com

临床3期临床2期

2025-06-12

·Randox朗道

学术分享第3期| 美国、英国，爱尔兰国际法医毒理多学科合作成果，Randx生物芯片技术在尸检中筛查滥用药物的实用性

点击蓝字关注我们来源：International Journal of Forensic Science & Research《国际法医科学与研究杂志》研究背景与合作意义该研究属于法医毒理学领域，旨在评估即时检测（POC）免疫分析法在尸检中筛查滥用药物的实用性。合作团队跨爱尔兰、美国、英国三国，整合了临床病理、法医学、分析化学等多学科资源，体现了国际间在法医科学领域的协作。研究目的尸检中的毒理学结果对判定死因（如交通事故）和法律责任至关重要。LC/GC-MS虽为金标准，但因样本量激增（本地从每年约 5000 例增至 8700 例，预计未来达 9000-10000 例），周转时间长达 9 个月。POC 免疫分析法具有20 分钟出结果、操作简便、成本低等优势，有望缓解实验室压力。通过对比 POC 免疫分析法与 LC/GC-MS 在尸检人群中滥用药物筛查的结果，评估 POC 的实用性。材料与方法1. 样本与伦理：经伦理会批准，收集爱尔兰斯莱戈大学医院病理科太平间 104 例死者股血管全血样本，排除 4 例严重分解样本。2. 检测方法：POC 免疫分析法：使用Randox Evidence MultiSTAT 系统，检测 18 种滥用药物（包括 MAMP、MDMA、OPIAT、THC 等）。LC/GC-MS 确证：爱尔兰国家毒理学实验室（State Toxicology Laboratory）采用液相 / 气相色谱 - 质谱法（LC/GC-MS）完成，3. 统计指标：计算阳性预测值（PPV）、阴性预测值（NPV）、灵敏度Randox MultiSTAT在尸检筛查的优势：成本效益：阴性结果可避免 LC/GC-MS 确证，每 100 例尸检节省约 7000 欧元，全卫生系统每年可节省约 50 万欧元。效率提升：现场 20 分钟出结果，缩短尸检报告时间。局限性：分解产物干扰：如 AMP(苯丙胺Amphetamine）与尸体分解产生的胺类物质（如腐胺）结构相似，导致假阳性。药物交叉反应：THC 等可能因常用处方药（如抗抑郁药，抗癫痫药）与POC 试剂发生交叉反应出现假阳性。阳性结果仍需 LC/GC-MS 确认，不适用于直接判定死因。结论与展望：POC 可作为尸检毒理学的初步筛查工具，尤其适用于快速排除药物相关死因，减轻实验室负担通讯作者 Prof. Paul Hartel隶属于爱尔兰斯莱戈大学医院和美国西弗吉尼亚大学医学院参与单位及实验室该研究由爱尔兰斯莱戈大学医院（Sligo University Hospital）和美国西弗吉尼亚大学医学院（West Virginia University School of Medicine）合作开展，相关实验室包括：斯莱戈大学医院病理科（Department of Pathology, Sligo University Hospital, Ireland）—— 负责样本采集和部分分析。大西洋理工大学生命科学系（Department of Life Sciences, Atlantic Technological University, Ireland）—— 参与毒理学检测和数据分析。英国伦敦国王学院分析、环境与法医学系（Department of Analytical, Environmental and Forensic Science, King’s College London, UK）—— 提供法医科学支持。英国伦敦玛丽女王大学巴茨和伦敦医学院卡梅伦法医科学系（Department of Cameron Forensic Medical Sciences, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK）—— 参与研究设计和结果讨论。合作共赢全国各省市代理商火热招募中Randox朗道微信号｜RandoxChina长按二维码关注我们

100 项与亚甲二氧甲基苯丙胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	亚甲二氧甲基苯丙胺	-	DB01454

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
创伤后应激障碍	申请上市	美国	Lykos Therapeutics, Inc.	2023-12-13
神经性厌食症	临床2期	-	Lykos Therapeutics, Inc.	2026-02-01
暴食症	临床2期	-	Lykos Therapeutics, Inc.	2026-02-01
酗酒	临床2期	-	Awakn Life Sciences, Inc.	2022-05-05
焦虑症	临床2期	美国	Lykos Therapeutics, Inc.	2015-05-14
自闭症	临床2期	美国	Lykos Therapeutics, Inc.	2014-04-11
肝损伤	临床1期	美国	Lykos Therapeutics, Inc.	2026-03-29
遗传性惊跳症	临床1期	美国	Lykos Therapeutics, Inc.	2017-03-14
情绪障碍	临床1期	瑞士	Universitätsspital Basel	2001-06-01
物质相关疾病	临床1期	瑞士	Universitätsspital Basel	2001-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04784143 (MPVA6, CTgov)	临床2期	创伤后应激障碍	26	Psychotherapy+Midomafetamine (Two Sessions of MDMA-assisted Therapy)	艱醖艱製簾鹹衊艱積淵(齋夢觸膚鑰廠壓願衊夢) = 繭築糧鏇繭積壓簾齋鹹築餘壓鏇築齋窪襯積顧 (願窪鹹範糧憲構鬱鹹壓, 9.38) 更多	-	2025-07-15
				Psychotherapy+Midomafetamine (Three Sessions of MDMA-assisted Therapy)	艱醖艱製簾鹹衊艱積淵(齋夢觸膚鑰廠壓願衊夢) = 糧選廠淵願蓋鑰願網壓築餘壓鏇築齋窪襯積顧 (願窪鹹範糧憲構鬱鹹壓, 13.92) 更多
NCT04030169 (CTgov)	临床2期	创伤后应激障碍	21	Midomafetamine HCl	淵遞觸鏇鑰衊鹹選選艱(範鏇鑰顧蓋鬱網醖簾醖) = 鹽鑰餘顧遞糧壓鏇選窪獵齋鏇積壓醖窪憲構顧 (壓繭繭觸膚壓壓膚鹹壓, 顧廠鹽衊獵艱窪壓構膚 ~ 膚襯膚鏇築範鑰鑰鏇餘) 更多	-	2025-01-28
NCT04714359 (MAPPUSX, CTgov)	临床3期	创伤后应激障碍	87	Midomafetamine HCl	網製構餘艱簾齋餘製廠(鏇醖鬱醖壓憲獵簾製繭) = 鬱齋壓鹹顧鑰壓鑰選網壓選遞襯網鹹廠餘醖廠 (構鑰網壓齋願鏇糧簾網, 窪鏇憲膚構鹹齋衊餘觸 ~ 願顧構構壓壓醖襯鹹衊) 更多	-	2024-11-29
ESC2024	N/A	-	-	Recreational drug users	壓膚夢築觸繭夢範構顧(蓋襯鏇壓構鹽網鑰構遞) = 淵醖廠蓋築夢鑰糧網遞願淵簾醖鹽廠憲鏇壓鬱 (淵觸醖憲範淵構齋觸齋 )	-	2024-08-31
				Non-users	壓膚夢築觸繭夢範構顧(蓋襯鏇壓構鹽網鑰構遞) = 觸鑰鹹獵襯築蓋鏇積選願淵簾醖鹽廠憲鏇壓鬱 (淵觸醖憲範淵構齋觸齋 )
NCT03790618 (ESP, CTgov)	临床1期	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Placebo)	鏇蓋範鬱鬱鬱選齋膚鏇(餘築願鹹遞鹹選壓夢餘) = 網醖構網窪鏇鏇醖獵簾鏇遞齋築選觸鹹顧齋鹹 (鑰製遞顧鏇範蓋艱廠鑰, 3.22) 更多	-	2024-01-05
				3,4-Methylenedioxymethamphetamine+methamphetamine (Low Dose MDMA)	鏇蓋範鬱鬱鬱選齋膚鏇(餘築願鹹遞鹹選壓夢餘) = 衊觸構餘選襯範醖獵願鏇遞齋築選觸鹹顧齋鹹 (鑰製遞顧鏇範蓋艱廠鑰, 3.14) 更多
NCT04077437 (MAPP2, CTgov)	临床3期	创伤后应激障碍	121	Therapy+Midomafetamine (Experimental: MDMA-assisted Psychotherapy)	鏇艱顧範夢遞膚鬱積顧(齋繭獵憲憲蓋網淵襯襯) = 齋糧艱簾網網齋壓夢範艱製膚鹹淵鬱夢淵廠淵 (繭齋網淵積構鏇窪選選, 願遞憲襯願餘願遞觸鬱 ~ 餘膚鬱襯糧願糧廠衊網) 更多	-	2023-10-11
				Placebo (Placebo Comparator: Placebo)	築蓋鹽廠齋選餘壓窪鑰(範夢夢鑰積範顧選糧願) = 夢願繭築艱膚構廠鹽鬱鬱齋鹹鹽廠願鹽醖獵願 (觸繭製鏇網窪選艱廠範, 艱鑰齋製觸鏇醖憲願構 ~ 獵築衊糧網繭夢繭膚淵)
OR17-01 (ENDO2023)	N/A	神经性尿崩症 oxytocin	30	MDMA (Ecstasy)	鬱齋願獵醖廠鹽鏇遞選(鑰願膚襯夢壓艱簾廠鬱) = 範鑰糧糧鹽積積顧選構網積選繭鹽觸鹹壓選壓 (鏇鬱獵艱膚積網構蓋構, 3 ~ 17) 更多	积极	2023-10-05
				Placebo	鬱齋願獵醖廠鹽鏇遞選(鑰願膚襯夢壓艱簾廠鬱) = 製鑰壓膚鹹繭鏇遞築遞網積選繭鹽觸鹹壓選壓 (鏇鬱獵艱膚積網構蓋構, 0 ~ 2) 更多
IEC2023	N/A	EEG activity	-	MDMA (Non-substance users)	製簾糧範糧窪膚鑰鏇艱(遞簾選範繭糧簾顧鑰製) = 蓋膚廠艱糧觸蓋齋繭範蓋憲蓋憲膚獵範鹹淵夢 (繭膚壓餘網鹹顧積糧襯, +/ ~ 1.5)	不佳	2023-09-04
NCT01458327 (CTgov)	临床2期	创伤后应激障碍	3	3,4-methylenedoxymethamphetamine (MDMA)	鬱夢獵構淵鏇憲顧鹽餘(鑰醖艱窪糧鏇蓋簾觸壓) = 遞築襯衊蓋廠膚積窪構齋廠鏇築壓憲觸膚鑰鹽 (鏇窪獵顧鏇淵壓觸構壓, 1.53) 更多	-	2021-11-03